Objective To investigate the effect of Tanreqing injection assisted ganciclovir on children with respiratory syncytial virus pneumonia . Methods 145 cases of RSVP pediatric patientsin from February 2013 to January 2016 in our hospital were retrospectively chosen,according to different drug regimen,they were divided into two groups,the contronl group of 71 cases with ganciclovir injection treatment and study group of 74 cases,with Tanreqing injection treatment on the basis of the contronl group.The blood gas analysis was performed on the arterial blood of the two groups before treatment and 7 and 14 days after continuous administration.The changes of blood gas indexes (pH,PaO2,PaCO2) were compared.The lung rales, wheezing, fever, cough, wheeze disappearance of time and side effects of the children were recorded.Results After 7 and 14 days of treatment, the Ph of blood gas parameters in the study group were (7.38 ±0.21) and (7.41 ±0.26), the level of PaO2 were (96.45 ±4.06) mmHg and (98.84 ± 5.27) mmHg,which were significantly higher than those of the control group (P<0.05);the level of PaCO2 in the study group were(45.02 ±4.23) mmHg and (41.26 ±3.16) mmHg, which were significantly lower than those in the contronl group (P<0.05).The rale resorption time in the study group was (4.47 ±1.06) days, the duration of wheezing subsided was (5.03 ±0.43) days, the duration of wheezing was (4.89 ±0.72) days, the duration of fever subsided was (2.46 ±0.32) days, the duration of cough was (8.41 ±1.54) days,were significantly lower than the control group(P<0.05).The adverse reaction rate in the study group was 8.11%, significantly lower than that in the control group 21.13%(P<0.05).Conclusion The combination of Tanreqing injection combined with ganciclovir has a good effect on children with RSVP , and can significantly shorten the time of clinical evidences such as wheezing, wheezing and pulmonary rales, and improve the blood gas level in children,reduce adverse reactions.

OBJECTIVE: To discuss the significance of Entecavir(ETV) in the treatment of chronic serious hepatitis B(HBV).METHODS: 54 patients with chronic serious hepatitis B were assigned to receive combined therapy in which antiviral drugs such as interferon and(or) nucleoside(acid) analogues antiviral drugs were excluded(control group,n=26) or combined therapy in combination with entecavir(0.5 mg?d-1) qd(treatment group,n=28).The course of treatment in both groups were 6 weeks.The hepatic function,HBV markers and HBV-DNA quantitation were deteted every two weeks.The improvement rate of patients after the completion of treatment were recorded.RESULTS: In the follow-up of six weeks,serum HBV-DNA and total bilirubin levels decreased markedly,and significant difference was noted between compared with the control group;ALT,AST,ALB and PT decreased in both groups,but the differnces between the two groups were not significant;there was no signficnant differnce in improvement rate between the treatment group and the control group(89.3% versus 84.6%).CONCLUSION: Entecavir can rapidly lower serum HBV-DNA level,downregulate bilirubin level,improve liver function,improve patients prognosis in patients with hepatitis B,thus it can be used to treat serious hepatitis B.However,used in short term,the survival rate of patients with severe hepatitis B can hardly be improved.